Blue Trust Inc. Reduces Position in TG Therapeutics, Inc. $TGTX

Blue Trust Inc. cut its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 29.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,507 shares of the biopharmaceutical company’s stock after selling 616 shares during the period. Blue Trust Inc.’s holdings in TG Therapeutics were worth $54,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. CWM LLC grew its position in shares of TG Therapeutics by 16.2% in the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 290 shares during the last quarter. Golden State Wealth Management LLC grew its position in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 433 shares during the last quarter. Kingswood Wealth Advisors LLC grew its position in shares of TG Therapeutics by 6.4% in the 2nd quarter. Kingswood Wealth Advisors LLC now owns 8,284 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 500 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of TG Therapeutics by 0.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 63,400 shares of the biopharmaceutical company’s stock valued at $2,282,000 after buying an additional 500 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its position in shares of TG Therapeutics by 26.8% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,416 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 511 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.64% of the company’s stock.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They issued a “buy” rating and a $60.00 target price on the stock. B. Riley increased their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average price target of $49.00.

TG Therapeutics Trading Down 0.6%

Shares of TG Therapeutics stock opened at $34.67 on Friday. TG Therapeutics, Inc. has a 1 year low of $22.61 and a 1 year high of $46.48. The company has a market capitalization of $5.50 billion, a P/E ratio of 93.70 and a beta of 1.97. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The company’s fifty day moving average is $32.18 and its two-hundred day moving average is $35.04.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. During the same quarter last year, the business posted $0.04 EPS. The firm’s revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.